Database : HANSEN Search on : RIFAMPINA [Subject descriptor] References found : 172 [refine] Displaying: 1 .. 20   in format [Detailed]

page 1 de 9

go to page

1 / 172

HANSEN

select to print

Id: 19948 Author: Ganapati, R; Pai, V. V; Shroff, H. J; Gandewar, Kailas. Title: Rate of decline in bacterial index in leprosy; observations after three different chemotherapeutic interventions. Source: Int. J. Lepr;65(2):264-266, Jun. 1997. tab, graf. Descriptors: Hanseníase Dimorfa/quimioter Hanseníase Dimorfa/microbiol Hanseníase Virchowiana/quimioter Hanseníase Virchowiana/microbiol Rifampina/uso terap Ofloxacino/uso terap Location: BR191.1

2 / 172

HANSEN

select to print

Id: 19938 Author: Mane, Ibrahima; Cartel, Jean-Louis; Grosset, Jacques-Henri. Title: Field trial on efficacy of supervised monthly dose of 600mg rifampin, 400mg ofloxacin and 100mg minocycline for the treatment of leprosy; first results. Source: Int. J. Lepr;65(2):224-229, Jun. 1997. tab. Abstract: In 1995, a field trial was implemented in Senegal in order to evaluate the efficacy of a regimen based on the monthly supervised intake of rifampin 600 mg, ofloxacin 400 mg and minocycline 100 mg to treat leprosy. During the first year of the trial, 220 patients with active leprosy (newly detected or relapsing after dapsone monotherapy) were recruited: 102 paucibacillary (PB) (60 males and 42 females) and 118 multibacillary (MB) (71 males and 47 females). All of them accepted the new treatment (none requested to be preferably put under standard WHO/MDT), no clinical sign which could be considered as a toxic effect of the drug was noted, and none of the patients refused to continue treatment because of any clinical trouble. The compliance was excellent: the 113 patients (PB and MB) detected during the first 6 months of the trial have taken six monthly doses in 6 months, as planned. The rate of clearance and the progressive decrease of cutaneous lesions was satisfactory. Although it is too soon to give comprehensive results, it should be noted that no treatment failure was observed in the 56 PB patients who have completed treatment and have been followed up for 6 months. The long-term efficacy of the new regimen is to be evaluated on the rate of relapse during the years following the cessation of treatment. If that relapse rate is acceptable (similar to that observed in patients after treatment with current standard WHO/ MDT), the new regimen could be a solution to treat, for instance, patients very irregular and/or living in remote or inaccessible areas since no selection of rifampin-resistant Mycobacterium leprae should be possible (a monthly dose of ofloxacin and minocycline being as effective as a dose of dapsone and clofazimine taken daily for 1 month). Nevertheless, until longer term results of this and other trials become available, there is no justification for any change in the treatment strategy, and all leprosy patients should be put under standard WHO/MDT. (AU)^ien. Descriptors: Hanseníase/quimioter Rifampina/admin Rifampina/ef adv Rifampina/uso terap Ofloxacino/admin Ofloxacino/ef adv Ofloxacino/uso terap Minociclina/admin Minociclina/ef adv Minociclina/uso terap Limits: Humanos Masculino Feminino Location: BR191.1

3 / 172

HANSEN

select to print Texto Completo-en

Id: 19767 Author: Becx-Bleuminck, Marijke. Title: Operational aspects of multidrug therapy. Source: Int J Lepr;57(2):540-551, June 1989. ^btab. Descriptors: Hanseníase/quimioter Rifampina/uso terap Amidas/uso terap Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n2/v57n2soalec02.pdf / en Location: Br191.1

4 / 172

HANSEN

select to print Texto Completo-en

Id: 19757 Author: Girdhar, Anita; Mishra, Brajendra; Lavania, Ravinder K; Bagga, Ashok K; Malaviya, Govind N; Girdhar, Bhawneshwar K. Title: Leprosy in infants - report of two cases. Source: Int J Lepr;57(2):472-475, June 1989. ^bilus. Descriptors: Hanseníase/diag Hanseníase/quimioter Hanseníase/patol Rifampina/uso terap Dapsona/uso terap Limits: Humanos Feminino Lactente Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n2/v57n2a04.pdf / en Location: Br191.1

5 / 172

HANSEN

select to print Texto Completo-en

Id: 19755 Author: Katoch, Kiran; Ramanathan, Usha; Natrajan, Mohan; Bagga, Ashok K; Bhatia, AS; Saxena, RK; Ramu, Gopal. Title: Relapses in paucibacillary patients after treatment with three short term regimens containing rifampin. Source: Int J Lepr;57(2):458-464, June 1989. ^btab. Abstract: Three multidrug regimens all containing rifampin and dapsone have been tried for the treatment of 278 cases of paucibacillary leprosy. Regimen I was the one recommended by the WHO Study Group. Regimen II was the same as Regimen I with depsone alone continued for a further 6 months. Regimen III was the same as Regimen II but rifampin was given daily for the first 7 days. The patients were comparable with regard to disease classification, lepromin status, bacteriological status, and number of lesions. As reported earlier, the disease inactivity rates by 1 year of treatment were much greater with Regimens II and III than with Regimen I (94% and 97% vs 76%). Early reaction was seen in 6% of those in Regimen III and in none in Regimens I and II. Late reaction was observed in 9% of those in Regimen I and none in Regimens II and III. During 3 1/2 years of follow up, 13% of the cases in Regimen I, 1% in Regimen II, and 2% in Regimen III relapsed. Since the patients in the three regimens were otherwise comparable, it is concluded that the high inactivity rate, low relapse rate (1%-2%), and no early or late reaction as observed in Regimen II patients were because of adequate treatment^ien. Descriptors: Dapsona/admin Dapsona/uso terap Rifampina/admin Rifampina/uso terap Hanseníase/microbiol Hanseníase/patol Limits: Humanos Masculino Feminino Adulto Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n2/v57n2a02.pdf / en Location: Br191.1

6 / 172

HANSEN

select to print Texto Completo-en

Id: 19734 Author: Grosset, Jacques H; Guelpa-Lauras, Claire-Cécile; Bobin, Pierre; Brucker, Gilles; Cartel, Jean-Louis; Constant-Desportes, Monique; Flageul, Béatrice; Frédéric, Micheline; Guillaume, Jean-Claude; Millan, Jacques. Title: Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin. Source: Int J Lep;57(3):607-614, sept. 1989. ^btab. Abstract: Among 39 strains of Mycobacterium leprae isolated from patients with multibacillary leprosy who relapsed after treatment with rifampin (RMP), 22 strains were resistant to RMP and 17 were susceptible. All of the RMP-resistant strains were recovered from patients who had been treated with more than 50 doses of RMP, usually given as monotherapy. RMP-susceptible strains were recovered from only six patients who had received more than 50 doses of RMP, and from 11 patients who had received no more than seven doses. The median time to relapse after the beginning of RMP therapy was 9 years (range 1-12 years) among the patients harboring RMP-resistant strains of M. leprae, and the median time to relapse after discontinuation of RMP treatment was 7 years (range 1-11 years) among the patients harboring RMP-susceptible strains. These data suggest that monotherapy with more than a few doses of RMP can be responsible for the emergence of RMP-resistant strains of M. leprae, thus emphasizing the need to employ RMP only in combination with other effective drugs in the chemotherapy of multibacillary leprosy. Descriptors: Hanseníase/quimioter Hanseníase/terap Rifampina/uso terap Limits: Humanos Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n3/v57n3a02.pdf / en Location: Br191.1

7 / 172

HANSEN

select to print Texto Completo-en

Id: 19687 Author: anon. Title: Clinical Notes: "Flu" Syndrome Due to Rifampin; Experience with Four Cases. Source: Int. J. Lepr;63(1):92-94, 1995. ^btab. Descriptors: Rifampina/imunol Hanseníase/quimioter Hanseníase/imunol Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1995/pdf/v63n1/v63n1clinot.pdf / en Location: BR191.1

8 / 172

HANSEN

select to print Texto Completo-en

Id: 19591 Author: Cartel, Jean-Louis; Chanteau, Suzanne; Boutin, Jean-Paul; Taylor, Richard; Plichart, Régis; Roux, Jean; Celerier, Philippe; Grosset, Jacques-Henri. Title: Implementation of chemoprophylaxis of leprosy in the southern marquesas with a single dose of 25 mg kg rifampin. Source: Int. J. Lep;57(4):810-816, dec. 1989. ^btab, ^bgraf. Abstract: Between 1967 and 1987 in the Southern Marquesas, a remote archipelago in French Polynesia, the detection rate of leprosy was 48.9 per 100,000 when it was 8.6 per 100,000 for French Polynesia as a whole. In 1988, a program of chemoprophylaxis of leprosy with a single dose of 25 mg/kg rifampin was implemented, and 2751 persons (98.7% of the population) were treated in the Southern Marquesas. In addition, 678 South Marquesans and 2466 members of their families living in the Northern Marquesas and in the Society Archipelago, received the same chemoprophylaxis. Among 2676 persons studied in the Southern Marquesas (97.4% of the treated population), 130 had elevated IgM anti-phenolic glycolipid-I antibodies by ELISA without any evidence of leprosy. The onset of a skin lesion of borderline leprosy in a boy 3 months after chemoprophylaxis raises the question of the nature of such a skin lesion and, indirectly, of the effectiveness of the chemoprophylaxis. Descriptors: Hanseníase/quimioter Hanseníase/imunol Hanseníase/terap Rifampina/imunol Rifampina/uso terap Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n4/v57n4a09.pdf / en Location: Br191.1

9 / 172

HANSEN

select to print Texto Completo-en

Id: 19548 Author: Rea, Thomas H. Title: Trials of Daily, long-term minocycline and rifampin of clarithromycin and rifampin in the treatment of borderlinne lepromatous and lepromatous leprosy. Source: Int. J. Lepr;68(2):129-135, Jun., 2000. graf. Abstract: Daily, long-term treatment with minocycline 100 mg and rifampin 600 mg was initiated in 24 previously untreated borderline lepromatous (BL) and lepromatous (LL) patients for a total of 646 patient-months, averaging 26.9 months per patient. The same regimen was started in 12 BL and LL patients having a bacteriologic relapse for a total of 379 patient-months, averaging 32.5 months per patient, and in 12 patients judged to be at high risk for relapse for a total of 354 patient-months, averaging 29.5 months per patient. Daily, long-term treatment with clarithromycin 500 mg and rifampin 600 mg was initiated in 8 previously untreated BL and LL patients for a total of 174 patient-months, averaging 21.8 months per patient. The results in these 56 patients were compared to those obtained in 34 previously untreated BL and LL patients who were treated concurrently receiving daily, long-term dapsone 100 mg and rifampin 600 mg. No evidence of dangerous drug reactions or bone marrow, kidney or liver toxicity was seen in any of these five patient groups. Drug intolerance in 10 of the 90 patients studied necessitated discontinuing the chosen regimen, 4 from rifampin, 3 from dapsone, 2 from minocycline and 1 of undetermined attribution. The use of either minocycline or clarithromycin in conjunction with rifampin appears to pose no great risk when used long term. (AU)^ien. Descriptors: Hanseníase Virchowiana/quimioter Hanseníase Virchowiana/imunol Minociclina/uso terap Rifampina/uso terap Claritromicina/uso terap Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/2000/pdf/v68n2/v68n2a02.pdf / en Location: BR191.1

10 / 172

HANSEN

select to print Texto Completo-en

Id: 19498 Author: Matsuoka, Masanori; Kashiwabara, Yoshiko; Namisato, Masako. Title: A Mycobacterium leprae isolate resistant to dapsone rifampin, ofloxacin and sparfloxacin. Source: Int. J. Lepr;68(4):452-455, Dec., 2000. tab. Abstract: Mycobacterium leprae were isolated from a Japanese patient, and susceptibility to antileprosy drugs was examined by the mouse foot pad method. The isolate was susceptible to clofazimine and clarithromycin, and resistant to dapsone, rifampin, ofloxacin and sparfloxacin. Mutations were identified in the genes associated with resistance to these drugs. The risk of the emergence of leprosy with multidrug resistance is emphasized. (AU)^ien. Descriptors: Mycobacterium leprae/imunol Rifampina/imunol Dapsona/imunol Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/2000/pdf/v68n4/v68n4a07.pdf / en Location: BR191.1

11 / 172

HANSEN

select to print Texto Completo-en

Id: 19474 Author: Namisato, Masako; Ogawa, Hideoki. Title: Serious side effects of rifampin on the course of WHO/MDT: a case report. Source: Int. J. Lepr;68(3):277-282, Sept., 2000. tab. Abstract: A male born in 1935 was diagnosed as having lepromatous leprosy when he was 17 years old. In addition to dapsone (DDS) monotherapy, he had been treated with rifampin (RMP) for 2 terms: first with 450 mg a day for 2 years when he was 39 years old; second with 150 mg a day for 2 months after a 1-year interval from the first regimen. During these entire courses with RMP, no complication was noted. When he was 64 years old in 1999, a diagnosis of relapsed borderline tuberculoid (BT) leprosy was made, and he was started on the multibacillary (MB) regimen of the World Health Organization multidrug therapy (WHO/MDT). After the third dose of monthly RMP, he developed a flu-like syndrome and went into shock. A few hours later, intravascular hemolysis occurred followed by acute renal failure. He was placed on hemodialysis for 7 series and recovered almost completely about 2 months later. The immune complexes with anti-RMP antibody followed by complement binding may have accounted for these symptoms. Twenty-four reported cases of leprosy who had developed side effects of RMP under an intermittent regimen were analyzed; 9 of the cases had had prior treatment with RMP but 15 had not. Adverse effects were more likely to occur in MB cases and were more frequent during the first 6 doses of intermittent regimens. The cases with prior treatment with RMP had had a higher incidence of serious complications such as marked hypotension, hemolysis and acute renal failure. However, many exceptions were also found, and we could not verify any fully dependable factor(s) to predict the side effects of RMP. More field investigation is desirable, and monthly administration of RMP must be conducted under direct observation through the course of WHO/MDT. (AU)^ien. Descriptors: Hanseníase/quimioter Hanseníase/imunol Rifampina/ef adv Rifampina/uso terap Limits: Humanos Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/2000/pdf/v68n3/v68n3a05.pdf / en Location: BR191.1

12 / 172

HANSEN

select to print

Id: 18435 Author: GIRLING, D . J Title: Reaçoes adversas a rifampicina em esquemas contra a tuberculose Adverse reactions to rifampicin in schemes against tuberculosis- Source: s.l; s.n; 1977. 35 p. ilus, tab. Descriptors: RIFAMPINA/ef adv RIFAMPINA/sint quim RIFAMPINA/imunol RIFAMPINA/farmacol RIFAMPINA/uso terap HANSENIASE/quimioter Limits: ESTUDO COMPARATIVO Location: Br191.1; 01217/d.a

13 / 172

HANSEN

select to print

Id: 18426 Author: Teo, Steve K; Colburn, Wayne A; Tracewell, William G; Kook, Karin A; Stirling, David I; Jaworsky, Markian S; Scheffer, Michael A; Thomas, Steve D; Laskin, Oscar L Title: Clinical pharmacokinetics of thalidomide ..- Source: s.l; s.n; 2004. 17 p. ilus, tab, graf. Abstract: Thalidomide is a racemic glutamic acid derivative approved in the US for erythema nodosum leprosum, a complication of leprosy. In addition, its use in various inflammatory and oncologic conditions in being investigated. Thalidomide interconverts between the (R)- and (S)-enantiomers in plasma, with protein binding of 55% and 65%, respectively. More than 90% of the absorbed drug is excreted in the urine and faeces within 48 hours. Thalidomide is minimally metabolised by the liver, but is spontaneously hydrolysed into numerous renally excreted products. After a single oral dose of thalidomide 200mg (as the US-approved capsule formulation) in healthy volunteers, absorption is slow and extensive, resulting in a peak concentration (Cmax) of 1-2mg/L at 3-4 hours after administration, absorption lag time of 30 minutes, total exposure (AUCoo) of 18mg - h/L, apparent elimination half-life of 6 hours and apparent systemic clearence of 10 L/H. Thalidomide pharmacokinetics are best described by a one-comportment model with first-order absorption and elimination. Because of the low solubility of the drug in the gastrointestinal tract, thalidomide exhibits absorption rate-limited pharmacolinetics (the 'flip-flop' phenomenon), with its elimination rate being faster than in absorption rate. The apparent elimination half-life of 6 hours therefore represents absorption, not elimination. The 'true' apparent volume of distribution was estimated to be 16L by use of the faster elimination-rate half-life. Multiple doses of thalidomide 200 mg/day over 21 days cause no change in the pharmacokinetics, with a steady-state Cmax (Cssmax) of 1.2 mg/L. Simulation of 400 and 800 mg/day also shows no accululation, with Css of 3.5 and 6.0 mg/L, respectively. Multiple-dose studies in cancer patients show pharmacokinetics comparable with those in healthy populations at similar dosages. Thalidomide exhibits a dose-proportional increase in AUC at doses from 50 to 400mg. Because of the low solubility of thalidomide Cmax is less than proportional to dose, and tmax is prolonged with increasing dose. Age, sex and smoking have no effect on the pharmacokinetics of thalidomide, and the effect of food is minimal. Thalidomide does not alter the pharmacokinetics of oral contraceptives, and is also unlikely to interact with warfarin and grapefruit juice. Since thalidomide is mainly hydrolysed and passively excreted, its pharmacokonetics are not expected to change in patients with impaired liver...(AU). Descriptors: TALIDOMIDA/admin TALIDOMIDA/sint quim TALIDOMIDA/contra TALIDOMIDA/hist TALIDOMIDA/isol TALIDOMIDA/farmacocin TALIDOMIDA/normas TALIDOMIDA/tox TALIDOMIDA/uso terap TALIDOMIDA/metab - ERITEMA NODOSO HANSENICO/quimioter  ERITEMA NODOSO/etiol  SINDROME DE IMUNODEFICIÊNCIA ADQUIRIDA FELINA/terap  ADMINISTRACAO ORAL  INTERACOES DE MEDICAMENTOS/fisiol  RIFAMPINA/antag  FENOBARBITAL/antag  CIMETIDINA/antag  DILTIAZEM/antag  WARFARIN/antag Limits: HUMANO Location: BR191.1; 00948/s

14 / 172

HANSEN

select to print

Id: 18390 Author: Ebenezer, G. J; Norman, G; Joseph, G. A; Daniel, S; Job, C. K Title: Drug resistant-Mycobacterium leprae- results of mouse footpad studies from a laboratory in South India ..- Source: s.l; s.n; 2002. 12 p. tab. Abstract: Out of 265 biopsies of leprosy patients received at the Experimental Laboratory of Schieffelin Leprosy Research and Training Centre from 1987 to 1997 for evaluating resistant strains of M. leprae using the mouse footpad technique, 49 showed resistant strains of M. leprae to varying concentration of dapsone, rifampicin and clofazimine. 23 (47%) of these were from a control area. With 369 skin-smear positive multibacillary (MB) patients as the risk group (denominator), 23 (6.23%) were resistant to one or more drugs. 18 (4.88%) had dapsone resistance, 5 (1.36%) were resistant to rifampicin and 9 (2.44%) had resistance to low concentrations of clofazimine (0.0001%). Out of the 23 biopsies with drug resistance from the control area, primary dapsone resistance was seen in 7 (30%) biopsies and secondary dapsone resistance in 11 (48%). Primary rifampicin resitance was seen in 4 (17.4%) patients, secondary rifampicin resistance in 1 (4.35%) and primary clofazimine resistance in 7 (30%). 3 (13%) of the strains showed secondary clofazimine resistance. One biopsy had resistent strains to all the three drugs. In a control area where properly supervised effective multidrug therapy (MDT) was regularly administered over the years, the emergence of drug resistance is negligible. It may not be the case if the content, duration and regularity of the drug regimen were not satisfactory. Aware of the possible shortcomings in mass administration of MDT, it is emplasized that mouse footpad studies on drug resistance should be made available at least in endemic areas where the incidence of the disease has not changed despite good MDT coverage in order to monitor the emergence of drug resistance. Research into molecular biological identification of drug resistant-M.leprae should be intensified. These steps would help to institute timely measures to check the spread of any drug-resistant organisms in the community (AU). Descriptors: MYCOBACTERIUM LEPRAE/cresc MYCOBACTERIUM LEPRAE/isol MYCOBACTERIUM LEPRAE/metab MYCOBACTERIUM LEPRAE/patogen MYCOBACTERIUM LEPRAE/ultraest RESISTÊNCIA A DROGAS DAPSONA/uso terap CLOFAZIMINA/uso terap RIFAMPINA/uso terap TESTES DE SENSIBILIDADE MICROBIANA/métodos TESTES DE SENSIBILIDADE MICROBIANA/vet - HANSENIASE/clas  HANSENIASE/compl  HANSENIASE/quimioter  HANSENIASE/imunol  HANSENIASE/microbiol  HANSENIASE/patol  OFLOXACINO/uso terap  MINOCICLINA/uso terap Limits: HUMANO Location: BR191.1; 09299/s

15 / 172

HANSEN

select to print

Id: 18385 Author: Consigny, Sophie; Bentoucha, Abdelhalim; Bonnafous, Pascale; Grosset, Jacques; Ji, Baohong Title: Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice ..- Source: s.l; s.n; 2000. 3 p. tab. Abstract: Bactericidal activities of HMR 3647 (HMR), moxifloxacin (MXFX), and rifapentine (RPT) against Mycobacterium leprae, measured by the proportional bactericidal technique in the mouse footpad system, were compared with those of the established antileprosy drugs clarithromycin (CLARI), ofloxacin (OFLO), and rifampin (RMP. Administered in five daily doses of 100 mg/kg of body weight, HMR appeared slightly more bactericidal than CLARI. In a single dose, MXFX at 150 mg/kg was more active than the same dose of OFLO and displayed exactly the same level of activity as RMP at 10 mg/kg; the combination MXFX-minocycline (MINO) (MM) was more bactericidal than the combination OFLO-MINO (OM); RPT at 10mg/kg was more bactericidal than the same dose of RMP and even more active than the combination RMP-OFLO-MINO (ROM); the combination RPT-MXFX-MINO (PMM) killed 99.9% of viable M. leprae and was slighthy more bactericidal than RPT alone, indicating that the combination PMM showed an additive effect against M. leprae (AU). Descriptors: HANSENIASE/quimioter HANSENOSTATICOS/admin HANSENOSTATICOS/farmacol HANSENOSTATICOS/farmacocin HANSENOSTATICOS/uso terap MYCOBACTERIUM LEPRAE TESTES DE SENSIBILIDADE MICROBIANA/métodos DROGAS EM INVESTIGACAO/admin DROGAS EM INVESTIGACAO/anal DROGAS EM INVESTIGACAO/uso terap - BACTERICIDAS  QUIMIOTERAPIA COMBINADA  MYCOBACTERIUM LEPRAE/metab  MYCOBACTERIUM LEPRAE/fisiol  DAPSONA/uso terap  RIFAMPINA/uso terap  CLOFAZIMINA/uso terap  OFLOXACINO/uso terap  MINOCICLINA/uso terap  CLARITROMICINA/uso terap Limits: ESTUDO COMPARATIVO Location: BR191.1; 09311/s

16 / 172

HANSEN

select to print

Id: 18384 Author: Biswas, S; Mondal, K. K Title: Multidrug therapy in leprosy can prevent relapse- a retrospective study ..- Source: s.l; s.n; 2002. 6 p. . Abstract: A retrospective study was done at the Leprosy Control Unit (LCU) in Durgapur of Burdwan district, West Bengal, to determine the relapse rate following multidrug therapy (MDT). A total of 1581 patients (1276 PB and 305 MB) completed MDT regimens during a period of 5 years as per WHO recommendations and National Leprosy Eradication Programme (NLEP) guidelines. The treated patients were kept under surveillance as per NLEP guidelines and searched for relapses. The results of MDT were compared with those of pre-MDT (monotherapy) era at the same centre (total: 405 patients; PB-373, MB-32) andalso with those of the Leprosy Clinic in Gopalpur (only dapsone was given to a total of 189 patients, PB-167, MB-22) Following monotherapy, the relapse rate was 10.06% at the Gopalpur Leprosy Clinic and 12.4% at the Dargapur LCU during the 2 years (PB) and 5 years (MB) of surveillance, whereas following MDT no relapse case was encountered both in PB and MB cases during the surveillance periods recommended by WHO. The results of this study are comparable with those of ohter studies. Though a few studies showed relapses during long-term surveillance beyond the periods recommended by WHO, it is once again established that MDT can prevent relapse in leprosy (AU). Descriptors: HANSENIASE/quimioter HANSENIASE/epidemiol HANSENIASE/prev RECIDIVA/prev - HANSENOSTATICOS/admin  HANSENOSTATICOS/hist  HANSENOSTATICOS/normas  HANSENOSTATICOS/uso terap  CLOFAZIMINA/uso terap  DAPSONA/uso terap  RIFAMPINA/uso terap Limits: ESTUDO COMPARATIVO HUMANO Location: BR191.1; 09310/s

17 / 172

HANSEN

select to print

Id: 18294 Author: Wood, Leonard Title: A statistical analysis of two chemotherapy trials in lepromatous leprosy: I- The response to therapy as measured by inoculation of mice ..- Source: s.l; s.n; 1978. 10 p. tab. Abstract: Two recent trials of chemotherapy in relatively large numbers of patients with lepromatous leprosy generated data that permitted analysis of the effects of treatment regimens and of various pretreatment characteristics of the patients. The results of treatment were measured by inoculation of mice with Mycobacterium leprae recovered from skin biopsy specimens obtained from the patients at intervals during the trials. The pretreatment variables-sex, age histopathological and clinical classifications, logarithmic biopsy specimen (LAFB) - were found to be uniformly distributed among the 36 patients treated by regimens 1, 2, 4 and 5 of trial I. . The ten patients treated by regimen 3 were excluded from this analysis. These pretreatment variables were also found to be uniformly distributed among all 21 patients treated by the two regimens of trial II...(AU). Descriptors: HANSENIASE VIRCHOWIANA/clas HANSENIASE VIRCHOWIANA/quimioter HANSENIASE VIRCHOWIANA/fisiopatol DAPSONA/uso terap RIFAMPINA/uso terap CLOFAZIMINA/uso terap Limits: ESTUDO COMPARATIVO Location: BR191.1; 0296/S

18 / 172

HANSEN

select to print

Id: 18285 Author: Colin, M; Montaigne, E. de Title: Traitement de la maladie de Hansen lepromateuse par l'association de rifampicine et d'isoprodian ..- Source: s.l; s.n; 1980. 3 p. . Abstract: Thirty lepromatous patients were treated during 3 months. If clinical condition was notably improved, the bacillary index and the morphologic index remained almost un-changed and the histo-pathological features, advanced concurrently to the clinic aspects. (AU). Descriptors: HANSENIASE VIRCHOWIANA/terap HANSENIASE VIRCHOWIANA/compl HANSENIASE VIRCHOWIANA/microbiol HANSENIASE VIRCHOWIANA/patol QUIMIOTERAPIA COMBINADA - RIFAMPINA/uso terap  ISOPRODIAN/uso terap Limits: HUMANO Location: BR191.1; 00460/s

19 / 172

HANSEN

select to print

Id: 18229 Author: Leonard Wood Memorial*. Title: A statistical analysis of two chemotherapy trials in lepromatous leprosy: II. Interactions among patient variables ..- Source: s.l; s.n; 1978. 4 p. tab. Abstract: Interrelationship among six patient characteristics recorded upon entry the trial were analyzed for 67 patients with lepromatous and near-lepromatous leproay admitted into two chemotherapy trials. Sex was found to be significantly associated with age and with the histopathologic classification; disproportionately large numbers of older patients and of patients classified as borderline-lepromatous (BL) were males. Classifications of the disease process by clinical and histopathologic criteria were closely associated, but many patients classified BL on histopathological grounds were classified fully lepromatous by the clinical criteria. Measurments of the number of Mycobacterium leprae in the patients made by there methods were also significantly correlated. No significant correlations were found between either classification of the disease process on the hand, and any of the measurments of the numbers of organisms on the other (AU). Descriptors: HANSENIASE DIMORFA/terap HANSENIASE VIRCHOWIANA/terap CLOFAZIMINA/admin CLOFAZIMINA/farmacol CLOFAZIMINA/uso terap RIFAMPINA/uso terap DAPSONA/uso terap HANSENIASE DIMORFA/microbiol HANSENIASE DIMORFA/patol HANSENIASE VIRCHOWIANA/microbiol HANSENIASE VIRCHOWIANA/patol - QUIMIOTERAPIA COMBINADA  DROGAS EM INVESTIGACAO/admin  DROGAS EM INVESTIGACAO/uso terap Limits: ESTUDO COMPARATIVO HUMANO Location: BR191.1; 00294/s

20 / 172

HANSEN

select to print

Id: 18225 Author: Ebenezer, G. J; Norman, G; Joseph, G. A; Daniel, S; Job, C. K Title: Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India ..- Source: s.l; s.n; 2002. 12 p. tab. Abstract: Out of 265 biopsies of leprosy patients received at the Experimental Pathology Laboratory of Schieffelin Leprosy Research and Training Centre from 1987 to 1997 for evaluating resistant strains of M. leprae, using the mouse footpad technique, 49 showed resistant strains of M leprae to varying concentrations of dapsone, rifampicin and clofazimine. 23 (47%) of these were from a control area. With 369 skin-smear positive multibacillary (MB) patients as the risk group (denominator), 23 (6.23%) were resistant to one or more drugs. 18 (4.88%) had dapsone resistance, 5 (1.36%) were resistant to rifampicin and 9 (2.44%) had resistance to low concentrations of clofazimine (0.0001%). Out of the 23 biopsies with drug resistance from the control area, primary dapsone resistance was seen in 7 (30%) biopsies and secondary dapsone resistance in 11 (48%). Primary rifampicin resistance was seen in 4 (17.4%) patients, secondary rifampicin resistance in 1 (4.35%) and primary clofazimine resistance in 7 (30%). 3 (13%) of the strains showed secondary clofazimine resistance. One biopsy had resistant strains to all the three drugs. In a control area where properly supervised effective multidrug therapy (MDT) was regularly administered over the years, the emergence of drug resistance is negligible. It may not be the case if the content, duration and regularity of the drug regimen were not satisfactory. Aware of the possible shortcomings in mass administration of MDT, it is emphasized that mouse footpad studies on drug resistance should be made available at least in endemic areas where the incidence of the disease has not changed despite good MDT coverage in order to monitor the emergence of drug resistance. Research into molecular biological identification of drug resistant-M.leprae should be intensified. These steps would help to institute timely measures to check the spread of any drug-resistant organisms in the community. (AU). Descriptors: Clofazimina/PD Dapsona/PD Farmacorresistência Bacteriana Farmacorresistência Bacteriana Múltipla Índia Hansenostáticos/*PD Hanseníase/*DT/MI Camundongos Camundongos Endogâmicos CBA Testes de Sensibilidade Microbiana Mycobacterium leprae/*DE Rifampina/PD Limits: HUMANO ANIMAL MASCULINO FEMININO Location: BR191.1; 09179/S

---

page 1 de 9

go to page

Refine the search

Database : HANSEN

Advanced form

Search for : Free form

		Search	in field
1			WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
2	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
3	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type

Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO Latin American and Caribbean Center on Health Sciences Information